Literature DB >> 12954815

Arylacetamide kappa-opioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons.

S K Joshi1, Kenneth Lamb, K Bielefeldt, G F Gebhart.   

Abstract

We have previously reported that U50,488 [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide] enantiomers contribute to visceral antinociception by a nonopioid receptor-mediated blockade of sodium currents in colon sensory neurons. The present experiments were undertaken to examine the effect of arylacetamide kappa-opioid receptor agonists (kappa-ORAs) U50,488 and EMD 61,753 [(N-methyl-N-[1S)-1-phenyl)-2-(13S))-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenylacetamide HCl] on tetrodotoxin-sensitive (TTX-S) and -resistant (TTX-R) sodium currents, and the mechanism of their sodium channel-blocking actions. Whole cell patch-clamp experiments were performed on colon sensory neurons from the S1 dorsal root ganglion identified by content of retrograde tracer 1.1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine metanesulfonate. The concentration-response curves of U50,488 and EMD 61,753, for tonic inhibition of total, TTX-S, and TTX-R sodium currents were similar (EC50 values for U50,488 and EMD 61,753 were 8.4 +/- 1.69 and 1.2 +/- 1.78 microM, respectively). In contrast, the peptide kappa-ORA dynorphin was without effect in these experiments. U50,488 (10 microM) shifted the voltage dependence of steady-state inactivation curves for total, TTX-S, and TTX-R currents to more negative potentials. Inhibition was present at holding potentials of -100 to -20 mV. After the tonic block elicited by 10 microM U50,488, repetitive stimulation with 5-ms depolarizing pulses at a frequency of 3 Hz further enhanced the inhibition of total, TTX-R, and TTX-S currents by 43.8 +/- 4.9, 46.2 +/- 4.9, and 40 +/- 3.2%, respectively. These results demonstrate that arylacetamide kappa-ORAs nonselectively inhibit voltage-evoked sodium currents in a manner similar to local anesthetics, by enhancing closed-state inactivation and induction of use-dependent block.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954815     DOI: 10.1124/jpet.103.052829

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

2.  Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats.

Authors:  C G Jolivalt; Y Jiang; J D Freshwater; G D Bartoszyk; N A Calcutt
Journal:  Diabetologia       Date:  2006-08-19       Impact factor: 10.122

3.  Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.

Authors:  Andrew C Gray; Paul J White; Ian M Coupar
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

4.  The κ-opioid receptor agonist U-50488 blocks Ca2+ channels in a voltage- and G protein-independent manner in sensory neurons.

Authors:  Bassil Hassan; Victor Ruiz-Velasco
Journal:  Reg Anesth Pain Med       Date:  2013 Jan-Feb       Impact factor: 6.288

5.  Early-in-life bladder inflammation alters U50,488H but not morphine-induced inhibition of visceromotor responses to urinary bladder distension.

Authors:  Amber D Shaffer; Timothy J Ness; Alan Randich
Journal:  Neurosci Lett       Date:  2012-11-29       Impact factor: 3.046

Review 6.  Visceral pain: the neurophysiological mechanism.

Authors:  Jyoti N Sengupta
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2008-09       Impact factor: 3.598

8.  Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.

Authors:  Allen W Mangel; Gareth A Hicks
Journal:  Clin Exp Gastroenterol       Date:  2012-01-12

9.  Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design.

Authors:  John Broad; Damien Maurel; Victor W S Kung; Gareth A Hicks; Michael Schemann; Michael R Barnes; Terrence P Kenakin; Sébastien Granier; Gareth J Sanger
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.